Table 3.
Concomitant medications most frequently used during double-blind treatment in short-term randomized, controlled TRD trials
| Women | Men | |||
|---|---|---|---|---|
| Specific or category of concomitant medication | Esketamine + antidepressant N = 282 |
Antidepressant + placebo N = 184 |
Esketamine + antidepressant N = 136 |
Antidepressant + placebo N = 103 |
| Benzodiazepine | 140 (49.6%) | 86 (46.7%) | 66 (48.5%) | 36 (35.0%) |
| Analgesic | 79 (28.0%) | 57 (31.0%) | 34 (25.0%) | 24 (23.3%) |
| Antihypertensive | 62 (22.0%) | 53 (28.8%) | 33 (24.3%) | 32 (31.1%) |
| Lipid-lowering agent | 45 (16.0%) | 36 (19.6%) | 32 (23.5%) | 28 (27.2%) |
| Proton pump inhibitor | 40 (14.2%) | 28 (15.2%) | 24 (17.6%) | 11 (10.7%) |
| Beta-blocker | 34 (12.1%) | 21 (11.4%) | 21 (15.4%) | 9 (8.7%) |
| Thyroid medications | 37 (13.1%) | 35 (19.0%) | 5 (3.7%) | 8 (7.8%) |
| Levothyroxine | 36 (12.8%) | 33 (17.9%) | 5 (3.7%) | 7 (6.8%) |
| Hormonal therapya | 49 (17.4%) | 24 (13.0%) | NA | NA |
| TRANSFORM-1/2 | ||||
| Pre-menopausal | 39/112 (34.8%) | 15/70 (21.4%) | ||
| Peri-menopausal | 6/15 (40.0%) | 2/9 (22.2%) | ||
| Post-menopausal | 4/108 (3.7%) | 4/65 (6.2%) | ||
| TRANSFORM-3 | 0/45 (0.0%) | 3/40 (7.5%) | ||
The table lists, in descending order of frequency for all patients, all specific or categories of concomitant medication with a usage rate during double-blind treatment of ≥ 10% in either treatment group, without regard to sex
aIncludes hormone replacement therapy and oral contraceptives